Research Papers:

CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype

Eleonora Duregon, Rebecca Senetta, Alessandra Pittaro, Ludovica Verdun di Cantogno, Giulia Stella, Pierpaolo De Blasi, Michele Zorzetto, Cristina Mantovani, Mauro Papotti and Paola Cassoni _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:29626-29636. https://doi.org/10.18632/oncotarget.4988

Metrics: PDF 1694 views  |   HTML 1825 views  |   ?  


Eleonora Duregon1,*, Rebecca Senetta5,*, Alessandra Pittaro5, Ludovica Verdun di Cantogno5, Giulia Stella2, Pierpaolo De Blasi3, Michele Zorzetto2, Cristina Mantovani4, Mauro Papotti1 and Paola Cassoni5

1 Department of Oncology, University of Torino at San Luigi Hospital, Orbassano, Turin, Italy

2 Laboratory of Biochemistry and Genetics, Pneumology Unit, Department of Molecular Medicine University and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

3 University of Torino and Collegio Carlo Alberto, Torino, Italy

4 Department of Oncology, Radiation Oncology, University of Torino, Italy

5 Department of Medical Sciences, University of Torino, Italy

* These authors have contributed equally to this work

Correspondence to:

Paola Cassoni, email:

Keywords: Caveolin 1, brain metastasis, non-small-cell lung cancer, radiotherapy

Received: April 10, 2015 Accepted: July 16, 2015 Published: July 22, 2015


Brain metastases develop in one-third of patients with non-small-cell lung cancer and are associated with a dismal prognosis, irrespective of surgery or chemo-radiotherapy. Pathological markers for predicting outcomes after surgical resection and radiotherapy responsiveness are still lacking. Caveolin 1 has been associated with chemo- and radioresistance in various tumors, including non-small-cell lung cancer. Here, caveolin 1 expression was assessed in a series of 69 brain metastases from non-small-cell lung cancer and matched primary tumors to determine its role in predicting survival and radiotherapy responsiveness. Only caveolin 1 expression in brain metastasis was associated with poor prognosis and an increased risk of death (log rank test, p = 0.015). Moreover, in the younger patients (median age of <54 years), caveolin 1 expression neutralized the favorable effect of young age on survival compared with the older patients. Among the radiotherapy-treated patients, an increased risk of death was detected in the group with caveolin 1-positive brain metastasis (14 out of 22 patients, HR=6.839, 95% CI 1.849 to 25.301, Wald test p = 0.004). Overall, caveolin 1 expression in brain metastasis from non-small-cell lung cancer is independently predictive of worse outcome and radioresistance and could become an additional tool for personalized therapy in the critical subset of brain-metastatic non-small-cell lung cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4988